Efavirenz to Dolutegravir Switch in Patients With CNS Toxicity

• ClinicalTrials.gov Identifier: NCT02285374
• Recruitment Status: Unknown
• First Posted: November 7, 2014
• Last Update Posted: November 7, 2014
• Sponsor: St Stephens Aids Trust
• Collaborator: ViiV Healthcare
• Information provided by (Responsible Party): St Stephens Aids Trust

Study Description

Brief Summary:

This is a phase IV, open label, multicentre trial that will be taking place at 4 sites in the United Kingdom (UK). Efavirenz which is taken in combination with Kivexa® or as part of the combination pill, Atripla® is a recommended firstline regimen for the treatment of Human Immunodeficiency Virus-1 (HIV- 1) infection. Treatment against the HIV virus is also referred to as antiretroviral therapy.

Toxicity is the most common reason for modification of firstline therapy. Central Nervous System (CNS) side effects such as difficulty with sleeping & bad dreams are common side effect of Efavirenz based therapy and is one of the most frequent reasons for switching or discontinuing highly active antiretroviral therapy.

Dolutegravir is within a novel class of antiretroviral agents licensed in the UK for the treatment of HIV. In combination with Truvada®, it showed fewer side effects when compared to Efavirenz in other clinical studies, where patients were starting HIV treatment for the first time, or switching from other agents.

The purpose of the study is to investigate the benefits of switching away from Eefavirenz (in combination with Kivexa® or as part of the combination pill, Atripla®) to Dolutegravir in patients with CNS side effects (such as difficulty with sleeping, bad dreams etc).

Condition or disease	Intervention/treatment	Phase
HIV	Drug: Dolutegravir, efavirenz, efavirenz/emtricitabine/tenofovir	Phase 4

Detailed Description:

The main aim of this study is to investigate the benefits of switching from Efavirenz (taken in combination with Kivexa®or as part of the combination pill, Atripla®) in patients with Central Nervous System (CNS) side effects (such as difficulty with sleeping, bad dreams etc). The study aims to investigate the effect of switching Efavirenz to Dolutegravir while continuing Truvada (tenofovir plus emtricitabine, two constituents of Atripla) or Kivexa. Dolutegravir will be the only new component of the combination.

In addition to the aims stated above, the study also aims:

To investigate whether switching to dolutegravir based combination Antiretroviral Therapy (cART) is associated with resolution of CNS toxicity (determined by CNS questionnaire) at 12 weeks post switch To investigate continued virological suppression at levels of <400 and <50 copies/ml in individuals switching to dolutegravircontaining cART at 4 and 12 weeks post switch To investigate changes in cluster of differentiation 4+ (CD4+) cell count in individuals switching to dolutegravircontaining cART over 12 weeks post switch To investigate the safety (laboratory and non CNS adverse events) of switching to dolutegravir based cART over 12 weeks post switch To investigate changes in quality of life in individuals switching to dolutegravir based cART as assessed by Quality of life (EuroQOL) questionnaires over 12 weeks post switch To investigate the impact of switching to dolutegravir based CART on anxiety and depression (as determined by Hospital Anxiety and Depression Score (HADS) over 12 weeks post switch To investigate changes in quality of sleep in individuals switching to dolutegravir based cART as per standardized sleep questionnaire at 4 and 12 weeks post switch To assess the impact of switching to dolutegravir based cART on adherence by standard questionnaire over 12 weeks post switch To investigate changes in neuropsychiatric function in individuals switching to dolutegravir based cART by CogState battery and Instrumental Activities of Daily Life (IADL) questionnaire over 12 weeks post switch To investigate changes in fasting cholesterol and triglycerides in individuals switching to dolutegravir based cART over 12 weekspost switch To investigate Efavirenz (EFV) plasma decay and its impact on Dolutegravir (DTG) concentrations following the switch (Maximum Concentration (Cmax), Minimum Concentration (Cmin), Area Under the concentration-time Curve (AUC) at weeks 1, 2 and 3 post switch) To investigate the association between genetic polymorphisms in drug disposition genes and drug exposure To assess changes in the levels of tryptophan, kynurenine, kynurenine/tryptophan ratio, neopterin, tumour necrosis factorα and interferonγ in plasma following treatment switch from efavirenz to dolutegravir.

To investigate the relationship between the immune activation biomarkers and the kynurenine/tryptophan ratio at baseline and post switch.

To investigate the relationship between the kynurenine/tryptophan ratio and measures of CNS toxicity and neurocognitive impairment at baseline and postswitch.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 40 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase IV Open-label, Multi-centre, Randomised, Dual-arm, Pilot Study to Assess the Feasibility of Switching Individuals Receiving Efavirenz With Continuing Central Nervous System (CNS) Toxicity, to Dolutegravir
• Study Start Date: November 2014
• Estimated Primary Completion Date: March 2015
• Estimated Study Completion Date: December 2015

Arms and Interventions

Arm	Intervention/treatment
Experimental: Arm 1; Truvada (tenofovir 245mg/emtricitabine 200mg) or Kivexa (abacavir 600mg/lamivudine 300mg) one tablet once daily plus Dolutegravir 50mg (one tablet) once daily	Drug: Dolutegravir, efavirenz, efavirenz/emtricitabine/tenofovir; Arm 1: Switch efavirenz to dolutegravir immediately (at baseline) for 12 weeks Arm 2: Continue on pre-study regimen (unchanged) for 4 weeks and then switch efavirenz to dolutegravir for 12 weeks; Other Name: Tivicay®, efavirenz, Atripla®
Experimental: Arm 2; Atripla (efavirenz 600mg, emtricitabine 200mg, tenofovir 245mg) one tablet once daily, or Truvada (tenofovir 245mg/emtricitabine 200mg) or Kivexa (abacavir 600mg/lamivudine 300mg) one tablet once daily plus efavirenz 600mg one tablet once daily for 4 weeks. At week 4, efavirenz is switched to Dolutegravir 50mg (one tablet) once daily	Drug: Dolutegravir, efavirenz, efavirenz/emtricitabine/tenofovir; Arm 1: Switch efavirenz to dolutegravir immediately (at baseline) for 12 weeks Arm 2: Continue on pre-study regimen (unchanged) for 4 weeks and then switch efavirenz to dolutegravir for 12 weeks; Other Name: Tivicay®, efavirenz, Atripla®

Outcome Measures

Primary Outcome Measures :

1. Rate of neuropsychiatric and central nervous system (CNS) toxicity [ Time Frame: 4 weeks post switch, day1 ]

   The rate of neuropsychiatric and central nervous system (CNS) toxicity (as measured by a questionnaire based on EFV Summary of Product Characteristics (SPC) and graded based on the ACTG adverse event scale) after 4 weeks of dual N(t)RTI plus DTG therapy:

   • Sum total of all grades of CNS adverse events
   • Median number of AIDS Clinical Trial Group (ACTG) grade 2-3 CNS adverse events Results 4 weeks post switch for each arm will be compared with baseline results and week 4 results will be compared between arms (ie 4 weeks post switch for arm 1 and day of switch for arm 2.).

Secondary Outcome Measures :

1. Rate of neuropsychiatric and central nervous system (CNS) toxicity [ Time Frame: 12 weeks post switch, day1 ]

   The rate of neuropsychiatric and central nervous system (CNS) toxicity (as measured by a questionnaire based on EFV SPC and graded based on the ACTG adverse event scale) after 12 weeks of dual Nucleoside/Nucleotide Reverse Transcriptase Inhibitor (N(t)RTI) plus DTG therapy:

   • Proportion of subjects with ACTG grade 2-3 events
   • Sum total of all grades of CNS adverse events
   • Median number of ACTG grade 2-3 CNS adverse events Results 12 weeks post switch for each arm will be compared with baseline results.
2. Virologic suppression [ Time Frame: 4 and 12 weeks post switch, day1 ]
   • Proportion of subjects maintaining virologic suppression to <50 and <400 copies/ml, 4 and 12 weeks post switch to dual N(t)RTI plus DTG
3. CD4 cell count and % [ Time Frame: 4 and 12 weeks post switch, day1 ]
   Change in CD4 cell count and % from baseline compared with 4 and 12 weeks post switch to dual N(t)RTI plus DTG
4. Quality of life [ Time Frame: 4 and 12 weeks post switch, day1 ]
   Changes in quality of life as assessed by Quality of life EuroQOL questionnaires at baseline, 4 and 12 weeks post switch
5. CNS toxicity [ Time Frame: 4 and 12 weeks post switch, day1 ]
   Change from baseline of CNS toxicity as measured by Hospital Anxiety and Depression (HADS) score at 4 and 12 weeks post switch to dual N(t)RTI plus DTG therapy, each compared with baseline
6. Sleep [ Time Frame: 4 and 12 weeks post switch, day1 ]
   Change in sleep from baseline compared with weeks 4 and 12 post switch to dual N(t)RTI plus DTG therapy, as determined by the Pittsburgh Sleep Score
7. Adherence [ Time Frame: 4 and 12 weeks post switch, day1 ]
   Change from baseline in adherence after 4 and 12 weeks of dual N(t)RTI plus DTG therapy as measured by the Medication Adherence Self-Report Inventory (M-MASRI) questionnaire
8. Neurocognitive assessment [ Time Frame: 4 and 12 weeks post switch, day1 ]
   Change from baseline in NeuroCognitive (NC) function after 4, and 12 weeks of dual N(t)RTI plus DTG therapy as determined by computerised NC assessment (CogState) and Instrumental Activities of Daily Life (IADL) questionnaire
9. Cholestrol levels [ Time Frame: 4 and 12 weeks post switch, day1 ]
   Change from baseline in median fasting cholesterol (total, HDL, LDL and total:HDL ratio) and triglycerides after switching to dual N(t)RTI plus DTG therapy at 4 and 12 weeks post switch
10. Laboratory values [ Time Frame: 4 and 12 weeks post switch, day1 ]
    Proportion of patients with grade 2-4 laboratory parameters (excluding lipids) after 4 and 12 weeks of dual N(t)RTI plus DTG therapy compared with baseline and proportion of patients with grade 2-4 non-CNS adverse events after 4 and 12 weeks of dual N(t)RTI plus DTG therapy compared with baseline
11. Efavirenz plasma concentration and Dolutegravir pharmacokinetics [ Time Frame: 1, 2 and 3 weeks post switch, day1 ]
    Efavirenz plasma concentration decay and DTG Pharmacokinetics (PK) (Cmax, Cmin, AUC) at weeks 1, 2 and 3 post switch
12. Protein levels [ Time Frame: 12 weeks post switch, day1 ]
    To assess changes in the levels of Triptophan (TRP), Kynurenic (KYN), KYN/TRP ratio, neomycin (NEO), Tumor Necrosis Factor (TNF-α) and Interferon (IFN-γ) in plasma at baseline/time of switch and 12 wks post-switch for all patients.
13. Difference in protein levels between the 2 arms [ Time Frame: 12 weeks post switch, day1 ]
    To assess differences between the immediate switch and delayed switch groups with regards to changes in the levels of TRP, KYN, KYN/TRP ratio, NEO, TNF-α and IFN-γ in plasma at baseline/time of switch and 12 wks post-switch
14. Relationship between immune activation markers and protein ratio [ Time Frame: Baseline and post switch, day1 ]
    To investigate the relationship between the IA biomarkers and the KYN/TRP ratio at baseline and post-switch.
15. Relationship between protein ratio and CNS toxicity and neurocognitive impairment [ Time Frame: Baseline and post switch, day1 ]
    To investigate the relationship between the KYN/TRP ratio and measures of CNS toxicity and NCI at baseline and post-switch.

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Is male or female aged 18 years or older
• Has HIV-1 infection documented in their medical notes
• Has signed the Informed Consent Form voluntarily
• Is willing to comply with the protocol requirements
• Is currently on an antiretroviral regimen comprising at least three licensed antiretroviral agents one of which is EFV, for at least 12 weeks
• No previous exposure to integrase inhibitors
• Has an HIV-plasma viral load at screening <400 copies/mL (single re-test allowed)
• Has a CD4 cell count at screening >50 cells/mm3
• Estimated glomerular filtration rate (MDRD) >50 ml/min.
• Has symptomatic CNS related toxicity associated with EFV at least Grade 2 by ACTG criteria
• If female and of childbearing potential, is using effective birth control methods (as agreed by the investigator) and is willing to continue practising these birth control methods during the trial and for at least 30 days after the end of the trial.

Exclusion Criteria:

• Infected with HIV-2
• Using any concomitant therapy disallowed as per SPC for the study drugs
• Has acute viral hepatitis including, but not limited to, A, B, or C
• Subjects positive for Hepatitis B at screening (+HBsAg), or anticipated need for Hepatitis C virus (HCV) therapy during the study
• Alanine aminotransferase (ALT) greater than or equal to 5 times the upper limit of normal (ULN), OR ALT greater than or equal to 3xULN and bilirubin greater than or equal to 1.5xULN (with >35% direct bilirubin)
• Unstable liver disease (as defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, or persistent jaundice), known biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones)
• Any investigational drug within 30 days prior to the trial drug administration
• Has received dolutegravir in the past
• Any clinical evidence of baseline resistance mutations
• History or presence of allergy to DTG or excipients (D-Mannitol, Microcystalline Cellulose, Povidone, Croscarmellose Sodium, Sodium Stearyl Fumarate, Talc, white film coat)
• Subjects with moderate to severe hepatic impairment (Class B or greater) as determined by Child-Pugh classification
• Moderate or severe renal impairment (creatinine clearance < 50ml/min by Cockroft-Gault method)
• If female, she is pregnant or breastfeeding
• Screening blood result with any grade 3/4 toxicity according to Division of AIDS (DAIDS) grading scale, except: asymptomatic grade 3 glucose, amylase or lipid elevation or asymptomatic grade 4 triglyceride elevation (re-test allowed).
• Any condition (including drug/alcohol abuse) or laboratory results which, in the investigator's opinion, interfere with assessments or completion of the trial.

Contacts and Locations

Contacts

Contact: Nuno Morgado; +44 (0)20 3315 3765; nuno.morgado@chelwest.nhs.uk

Locations

United Kingdom

Chelsea and Westminster Hospital

London, United Kingdom, SW10 9TH

Sponsors and Collaborators

St Stephens Aids Trust

ViiV Healthcare

Investigators

• Principal Investigator: Mark Nelson, MD; St Stephen's AIDS Trust

More Information

• Responsible Party: St Stephens Aids Trust
• ClinicalTrials.gov Identifier: NCT02285374 History of Changes
• Other Study ID Numbers: SSAT 056
• First Posted: November 7, 2014
• Last Update Posted: November 7, 2014
• Last Verified: October 2014

Additional relevant MeSH terms:

Tenofovir; Emtricitabine; Efavirenz; Dolutegravir; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Antiviral Agents; Anti-Infective Agents; Reverse Transcriptase Inhibitors; Nucleic Acid Synthesis Inhibitors; Enzyme Inhibitors; Molecular Mechanisms of Pharmacological Action; Anti-Retroviral Agents; Anti-HIV Agents; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2B6 Inducers; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 CYP3A Inducers; HIV Integrase Inhibitors; Integrase Inhibitors